NCT02598570View on ClinicalTrials.gov

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions
Lymphoma
Interventions
DRUG

duvelisib

Duvelisib will be administered orally as a fixed dose in 28-day cycles.

Trial Locations (3)

Unknown

Site Reference ID/Investigator# 141826, Aichi

Site Reference ID/Investigator# 141595, Fukuoka

Site Reference ID/Investigator# 141594, Tokyo

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
collaborator

Infinity Pharmaceuticals, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY